Avalyn
Seattle, Washington, United States · Biotechnology, Healthcare, Health Care
Avalyn is reimagining the future of pulmonary fibrosis treatment, with a pipeline of new inhaled formulations of approved medicines. Unlike currently available oral therapies, our inhaled approach allows us to tackle the underlying pathophysiology of pulmonary fibrosis at its source by safely delivering treatments directly into the lungs – improving tolerability by decreasing systemic exposure and
Key facts
- Headquarters
- Seattle, Washington, United States
- Employees
- 49
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (AVLN)
- Website
- avalynpharma.com
- Company page
Recent activity at Avalyn
- : SEC 8-K (5.02): On September 15, 2026, Avalyn Pharma Inc. appointed Dr. Robert Meyer as a Class II director of the Board, with his term set to expire at the annual meeting of stockholders in 2028. The appointment followed the recommendation of the Nominating and Corporate Governance Committee. Dr. Meyer is considered independent under Nasdaq's listing standards and has a notable background, having been a principal at Greenleaf Health Inc. from January 2018 to October 2024, which is a strategic consulting firm for the FDA. This strategic addition to the Board aims to enhance the company's governance and expertise in regulatory matters.
- : SEC 8-K (1.01): On June 29, 2026, Avalyn Pharma Inc. entered into a First Amendment to the Sublease, which modifies an existing Sublease Agreement with CRISPR Therapeutics, Inc. This amendment expands the leased space from approximately 8,774 to 13,708 square feet at 105 West First Street, Boston, Massachusetts. As a result, the Company’s future minimum lease payments will increase by approximately $924,000 over the remaining lease term. The agreement emphasizes the continuation of the previously established terms of the Sublease Agreement, maintaining its integrity while accommodating the expansion.
- : SEC 8-K (7.01): On June 17, 2026, Avalyn Pharma Inc. announced the completion of target enrollment in the Phase 2b MIST Trial for its product AP01 (Inhaled Pirfenidone), aimed at treating patients with Progressive Pulmonary Fibrosis. The enrollment completion signifies a critical milestone for the trial's progress, which could impact future developments and market potential for AP01 in this therapeutic area. The announcement was made via a press release issued on the same date. No financial amounts were specified in the filing.
- : SEC 8-K (7.01): On June 17, 2026, Avalyn Pharma Inc. disclosed through a press release that it has completed target enrollment in the Phase 2b MIST Trial for AP01 (Inhaled Pirfenidone) aimed at patients with Progressive Pulmonary Fibrosis. This significant milestone indicates the company's continued commitment to advancing its clinical trials in pulmonary medicine. The information was furnished under Item 7.01 of the Form 8-K and is intended for informational purposes without being considered 'filed' under the Securities Act. This development highlights progress in Avalyn's drug development pipeline and suggests potential future opportunities in treating this patient population.
- : Avalyn Pharma raises $100 million in a Series D round to develop inhaled medicines for pulmonary fibrosis, targeting effective delivery to the lungs.
- : Avalyn Strengthens Leadership Team with Key Appointments, including Dr. Craig Conoscenti as SVP, Clinical Development, and Jim Bishop as SVP, Business Operations
- : Avalyn Pharma
- : Avalyn Raises $175 Million In Oversubscribed Series C Financing To Advance Inhaled Pulmonary Fibrosis Programs Into Later Stage Clinical Studies
- : Avalyn Pharma Inc.
- : Genoa Pharmaceuticals, Inc.
Avalyn funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2025 | Series D | $100.0M |
| Oct 2023 | Venture | $189.2M |
| Sep 2023 | Series C | $175.0M |
| May 2020 | Venture | $35.5M |
| May 2017 | Venture | $18.2M |
Leadership
- A. Montgomery, Executive Officer, Director
- Tiba Aynechi, Director
- Sofia Ioannidou, Director
- Jonathan Leff, Director
- Niall O'Donnell, Director
- Ketan Patel, Director
- Robert Mittendorff, Director
- Heather Preston, Director
- Naveed Siddiqi, Director
- Ketan Patel, Director
- Niall O'Donnell, Director
- Jonathan M.D., Director
Verified email and direct lines for Avalyn’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Avalyn in the news
- Avalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile - GlobeNewswire (Sep 21, 2026)
- Avalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Yahoo Finance (Sep 08, 2026)
- Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials - MedCity News (Apr 30, 2026)
- Avalyn Announces Multiple Presentations at the European Respiratory Society International Congress 2026 - GlobeNewswire (Aug 24, 2026)
- Avalyn Announces First Patient Dosed in AURA Phase 2 - GlobeNewswire (Mar 23, 2026)
- Avalyn Announces Closing of Initial Public Offering and - GlobeNewswire (May 01, 2026)
- Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewswire (Aug 12, 2026)
- Avalyn Completes Target Enrollment in Phase 2b MIST Trial - GlobeNewswire (Jun 17, 2026)
Companies similar to Avalyn
- Shape Memory Medical · Biotechnology, Healthcare, Health Care
- Pharmazz · Biotechnology, Healthcare, Health Care
- Adagio Medical · Biotechnology, Healthcare, Health Care
- Beyond Air · Biotechnology, Healthcare, Health Care
- Omniscient Neurotechnology · Biotechnology, Healthcare, Health Care
About Avalyn: questions and answers
What does Avalyn do?
Avalyn is reimagining the future of pulmonary fibrosis treatment, with a pipeline of new inhaled formulations of approved medicines. Unlike currently available oral therapies, our inhaled approach allows us to tackle the underlying pathophysiology of pulmonary fibrosis at its source by safely delivering treatments directly into the lungs – improving tolerability by decreasing systemic exposure and
Where is Avalyn headquartered?
Avalyn is headquartered in Seattle, Washington, United States.
How many employees does Avalyn have?
Avalyn has about 49 employees.
Has Avalyn raised funding?
Yes. Fundz has recorded 5 funding events for Avalyn. The most recent, Series D of $100.0M, was in Jul 2025.
What is the latest news on Avalyn?
On Sep 15, 2026, SEC 8-K (5.02): On September 15, 2026, Avalyn Pharma Inc. appointed Dr. Robert Meyer as a Class II director of the Board, with his term set to expire at the annual meeting of stockholders in 2028. The appointment followed the recommendation of the Nominating and Corporate Governance Committee. Dr. M
Is Avalyn a public company?
Yes. Avalyn is publicly traded under the ticker AVLN.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy